Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials

BACKGROUND: Exenatide twice daily is a first-in-class glucagon-like peptide receptor agonist approved for the treatment of type 2 diabetes. The objective of this analysis was to evaluate the safety profile of exenatide twice daily and to compare its profile with that of a pooled comparator (placebo...

Descripción completa

Detalles Bibliográficos
Autores principales: MacConell, Leigh, Brown, Carl, Gurney, Kate, Han, Jenny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287409/
https://www.ncbi.nlm.nih.gov/pubmed/22375098
http://dx.doi.org/10.2147/DMSO.S28387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287409/
https://www.ncbi.nlm.nih.gov/pubmed/22375098
http://dx.doi.org/10.2147/DMSO.S28387

Ejemplares similares